Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00038077 · ClinicalTrials.gov registry record · Phase 3

Reversal of Ventricular Remodeling With Toprol-XL

A Phase 3 study of Heart Failure, Congestive, sponsored by AstraZeneca.

Completed
Registry status
Phase 3
Development phase
300
Enrollment target
20
Study locations

NCT00038077 is a Phase 3 study of Heart Failure, Congestive that has completed, run by AstraZeneca. The registered enrollment target is 300 participants, below the 633-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00038077, a Phase 3 study of Heart Failure, Congestive, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 3
Development phase
300 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease.

Conditions Studied

Heart Failure, Congestive

Interventions

  • DRUG Placebo
  • DRUG Seloken ZOK/Toprol-XL

Study Locations (20)

California

  • - Los Angeles
  • - Northridge
  • - Redondo Beach
  • - Riverside

Florida

  • - Clearwater
  • - Melbourne
  • - Vero Beach

Alabama

  • - Birmingham
  • - Mobile

Indiana

  • - Indianapolis
  • - Jeffersonville

Louisiana

  • - New Orleans
  • - Shreveport

Maryland

  • - Baltimore
  • - Salisbury

Arkansas

  • - Little Rock

Connecticut

  • Research Site - Farmington

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2001-08
Est. Completion 2003-09
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00038077

The ClinicalTrials.gov registry entry for NCT00038077 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 633-participant average among 33 other Heart Failure, Congestive trials with a reported enrollment target (53% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure, Congestive appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00038077 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT00038077 about?

NCT00038077 is a clinical study titled "Reversal of Ventricular Remodeling With Toprol-XL". The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease.

What is the current status of trial NCT00038077?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2001-08. Estimated completion is 2003-09.

What conditions does trial NCT00038077 study?

This clinical trial studies the following conditions: Heart Failure, Congestive.

What interventions are being tested in trial NCT00038077?

The interventions under investigation include: Placebo (DRUG), Seloken ZOK/Toprol-XL (DRUG).

Who is sponsoring clinical trial NCT00038077?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00038077 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure, Congestive

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure, Congestive

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.